Bicara Therapeutics Inc
BCAX17.270USD
-0.280-1.60%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
943.16MMarket Cap
LossP/E TTM
More Details of Bicara Therapeutics Inc Company
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.
Bicara Therapeutics Inc Info
Ticker SymbolBCAX
Company nameBicara Therapeutics Inc
IPO dateSep 13, 2024
CEOMazumdar (Claire)
Number of employees55
Security typeOrdinary Share
Fiscal year-endSep 13
Address116 Huntington Avenue Suite 703
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02116
Phone16174684219
Websitehttps://www.bicara.com/
Ticker SymbolBCAX
IPO dateSep 13, 2024
CEOMazumdar (Claire)
Company Executives of Bicara Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Claire Mazumdar, Ph.D.
Dr. Claire Mazumdar, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
309.89K
--
Dr. Ryan Cohlhepp, Pharm.D.
Dr. Ryan Cohlhepp, Pharm.D.
President, Chief Operating Officer
President, Chief Operating Officer
193.64K
-2.27%
Mr. Ivan Hyep
Mr. Ivan Hyep
Chief Financial Officer
Chief Financial Officer
145.35K
--
Dr. Nils Lonberg, Ph.D.
Dr. Nils Lonberg, Ph.D.
Independent Director
Independent Director
29.99K
--
Dr. Jake Simson, Ph.D.
Dr. Jake Simson, Ph.D.
Independent Director
Independent Director
--
--
Dr. David Raben, M.D.
Dr. David Raben, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Vijay Kuchroo, Ph.D.
Dr. Vijay Kuchroo, Ph.D.
Independent Director
Independent Director
--
--
Dr. Kiran Mazumdar Shaw
Dr. Kiran Mazumdar Shaw
Independent Director
Independent Director
--
--
Mr. Scott Robertson
Mr. Scott Robertson
Independent Director
Independent Director
--
--
Ms. Kate Haviland
Ms. Kate Haviland
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Claire Mazumdar, Ph.D.
Dr. Claire Mazumdar, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
309.89K
--
Dr. Ryan Cohlhepp, Pharm.D.
Dr. Ryan Cohlhepp, Pharm.D.
President, Chief Operating Officer
President, Chief Operating Officer
193.64K
-2.27%
Mr. Ivan Hyep
Mr. Ivan Hyep
Chief Financial Officer
Chief Financial Officer
145.35K
--
Dr. Nils Lonberg, Ph.D.
Dr. Nils Lonberg, Ph.D.
Independent Director
Independent Director
29.99K
--
Dr. Jake Simson, Ph.D.
Dr. Jake Simson, Ph.D.
Independent Director
Independent Director
--
--
Dr. David Raben, M.D.
Dr. David Raben, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
12.70%
Biocon Ltd.
10.08%
Invus Public Equities Advisors, LLC
9.52%
Vestal Point Capital, LP
9.31%
Red Tree Management, LLC
5.79%
Other
52.60%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
12.70%
Biocon Ltd.
10.08%
Invus Public Equities Advisors, LLC
9.52%
Vestal Point Capital, LP
9.31%
Red Tree Management, LLC
5.79%
Other
52.60%
Shareholder Types
Shareholders
Proportion
Investment Advisor
38.64%
Investment Advisor/Hedge Fund
18.96%
Venture Capital
16.79%
Corporation
10.73%
Hedge Fund
10.36%
Private Equity
5.50%
Individual Investor
1.45%
Research Firm
1.30%
Pension Fund
0.12%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
224
50.30M
113.92%
-100.00
2025Q3
224
50.29M
114.26%
-993.95K
2025Q2
199
51.28M
94.95%
+2.59M
2025Q1
174
48.67M
90.18%
-499.81K
2024Q4
146
46.83M
73.19%
+7.00M
2024Q3
76
39.67M
0.00%
+39.67M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
6.96M
12.75%
--
--
Jun 30, 2025
Biocon Ltd.
5.52M
10.12%
+5.41M
+4671.98%
Apr 14, 2025
Invus Public Equities Advisors, LLC
5.22M
9.56%
+1.95M
+59.68%
Jun 30, 2025
Vestal Point Capital, LP
5.00M
9.16%
+2.23M
+80.57%
Jun 30, 2025
Red Tree Management, LLC
3.17M
5.81%
--
--
Jun 30, 2025
TPG Capital, L.P.
3.01M
5.52%
--
--
Jun 30, 2025
Deep Track Capital LP
2.43M
4.45%
+426.66K
+21.33%
Jun 30, 2025
Omega Fund Management, LLC
2.20M
4.04%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
2.01M
3.68%
+914.14K
+83.78%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.88M
3.45%
+665.07K
+54.55%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.95%
Hypatia Women CEO ETF
0.37%
ALPS Medical Breakthroughs ETF
0.37%
Fidelity Enhanced Small Cap ETF
0.06%
T Rowe Price Small-Mid Cap ETF
0.05%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.03%
iShares Russell 2000 Value ETF
0.03%
ProShares Hedge Replication ETF
0.02%
iShares Russell 2000 ETF
0.02%
Global X Russell 2000 ETF
0.02%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.95%
Hypatia Women CEO ETF
Proportion0.37%
ALPS Medical Breakthroughs ETF
Proportion0.37%
Fidelity Enhanced Small Cap ETF
Proportion0.06%
T Rowe Price Small-Mid Cap ETF
Proportion0.05%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proportion0.03%
iShares Russell 2000 Value ETF
Proportion0.03%
ProShares Hedge Replication ETF
Proportion0.02%
iShares Russell 2000 ETF
Proportion0.02%
Global X Russell 2000 ETF
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Bicara Therapeutics Inc?
The top five shareholders of Bicara Therapeutics Inc are:
RA Capital Management, LP holds 6.96M shares, accounting for 12.75% of the total shares.
Biocon Ltd. holds 5.52M shares, accounting for 10.12% of the total shares.
Invus Public Equities Advisors, LLC holds 5.22M shares, accounting for 9.56% of the total shares.
Vestal Point Capital, LP holds 5.00M shares, accounting for 9.16% of the total shares.
Red Tree Management, LLC holds 3.17M shares, accounting for 5.81% of the total shares.
RA Capital Management, LP holds 6.96M shares, accounting for 12.75% of the total shares.
Biocon Ltd. holds 5.52M shares, accounting for 10.12% of the total shares.
Invus Public Equities Advisors, LLC holds 5.22M shares, accounting for 9.56% of the total shares.
Vestal Point Capital, LP holds 5.00M shares, accounting for 9.16% of the total shares.
Red Tree Management, LLC holds 3.17M shares, accounting for 5.81% of the total shares.
What are the top three shareholder types of Bicara Therapeutics Inc?
The top three shareholder types of Bicara Therapeutics Inc are:
RA Capital Management, LP
Biocon Ltd.
Invus Public Equities Advisors, LLC
RA Capital Management, LP
Biocon Ltd.
Invus Public Equities Advisors, LLC
How many institutions hold shares of Bicara Therapeutics Inc (BCAX)?
As of 2025Q4, 224 institutions hold shares of Bicara Therapeutics Inc, with a combined market value of approximately 50.30M, accounting for 113.92% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.35%.
What is the biggest source of revenue for Bicara Therapeutics Inc?
In --, the -- business generated the highest revenue for Bicara Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
